From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Variable | HR | 95.0 % CI | p |
---|---|---|---|
Gender | 0.973 | 0.545-1.738 | 0.927 |
Age of diagnosis | 1.003 | 0.998-1.008 | 0.205 |
RF positivity | 1.182 | 0.580-2.405 | 0.646 |
Anti-CCP positivity | 1.028 | 0.868-1.219 | 0.748 |
High AFR value in first admission | 0.774 | 0.441-1.357 | 0.375 |
Number of involved joints | 1.014 | 0.974-1.056 | 0.489 |
Large joint involvement | 0.584 | 0.210-1.623 | 0.302 |
Temporamandibular joint involvement | 1.336 | 0.567-3.146 | 0.508 |
Cervical involvement | 1.444 | 0.652-3.198 | 0.365 |
Accompanying diseases | 0.751 | 0.399-1.412 | 0.374 |
Uveitis | 0.624 | 0.268-1.451 | 0.273 |
İntra-articular injection | 0.627 | 0.354-1.111 | 0.110 |
Use of Biyolojical drug | 0.067 | 0.007-0.594 | 0.015 |
Systemic Steroid treatment | 0.828 | 0.493-1.390 | 0.475 |
Duration of systemic steroid treatment | 1.003 | 0.970-1.036 | 0.875 |
Amount of systemic steroid (mg/m2 ) | 1.000 | 1.000-1.000 | 0.865 |
Duration of MTX | 0.976 | 0.964-0.988 | 0.000 |
Duration of Biyolojic drug treatment | 0.971 | 0.956-0.986 | 0.000 |